The role of inflammation in the pathogenesis of heart failure

Current Cardiology Reports

Volumn 4, Issue 3, 2002, Pages 200-205

  Lisman, Kevin A ^a   Stetson, Sonny J ^a   Koerner, Michael M ^a   Farmer, John A ^a   Torre Amione, Guillermo ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALGORITHM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ALGORITHMS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-6; QUALITY OF LIFE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036581229     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-002-0051-3     Document Type: Article

References (22)

1. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691.
2. Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669-677.
3. Eichhorn EF, Bristow MR: The carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med 2001, 2:20-23.
4. Torre-Amione G, Kapadia S, Lee J, et al.: Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995, 92:1487-1493.
5. Torre-Amione G, Kapadia S, Lee J, et al.: Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996, 93:704-711.
6. Torre-Amione G, Kapadia S, Benedict C, et al.: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996, 27:1201-1206.
7. Bozkurt B, Torre-Amione G, Soram OZ, et al.: Results of a multidose phase I trial with tumor necrosis factor receptor (p75) fusion protein (Entanercept) in patients with heart failure. J Am Coll Cardiol 1999, 34:177-180. One of the first trials utilizing anti-TNF-a therapy in heart failure patients.
8. Deswal A, Bozkurt B, Seta Y, et al.: Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999, 99:3224-3226. Confirms safety of anti-TNF-a therapy in patients with heart failure.
9. Louis A, Cleland JG, Crabbe S, et al.: Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001, 3:381-387. Summary and preliminary data on large-scale use of anti-TNF-a therapy.
10. Torre-Amione G, Stetson SJ, Youker KA, et al.: Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : a potential mechanism for cardiac recovery. Circulation 1999, 100:1189-1193. Original study in which authors demonstrate the importance of volume and pressure overload in TNF-a expression.
11. Nakano M, Knowlton AA, Dibbs Z, et al.: Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation 1998, 97:1392-1400.
12. Bryant D, Becker L, Richardson J, et al.: Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor alpha. Circulation 1998, 97:1375-1381.
13. Mouthon L, Kaveri SV, Spalter SH, et al.: Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996, 104(Suppl 1):3-9.
14. McNamara DM, Holubkov R, Starling RC, et al.: Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001, 103:2254-2259. Pivotal trial showing no added benefit for IVIG in patients with new onset cardiomyopathy.
15. Gullestad L, Aass H, Fjeld JG, et al.: Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001, 103:220-225. Small trial showing benefit for prolonged administration of IVIG in patients with new-onset cardiomyopathy.
16. Muller J, Wallukat G, Dandel M, et al.: Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000, 101:385-391. Small trial showing benefit with immunoadsorption in patients with cardiomyopathy.
17. Shivji GM, Suzuki H, Mandel AS, et al.: The effects of VAS972 therapy on allergic contact hypersensitivity. J Cutaneous Med Surg 2000, 4:132-137. Use of novel immunomodulating therapy in contact hypersensitivity.
18. Freed I, Shahid S, Wang B, et al.: Role of transforming growth factor b-1 in the Th1/Th2 mechanisms of Vasogen's immune modulation therapy: potential role in psoriasis. J Invest Dermatol 2001, 117:388.
19. Packer M, Carver JR, Rodeheffer RJ, et al.: Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med 1991, 325:1468-1475.
20. Cohn JN, Goldstein SO, Greenberg BH, et al.: A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure: Vesnarinone Trial Investigators. N Engl J Med 1998, 339:1810-1816.
21. Packer M, Rouleau J, Swedberg K, et al.: Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study [abstract]. Circulation 1993, 88(suppl 1):I-301.
22. Kubo SH, Gollub S, Bourge R, et al.: Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trial. Circulation 1992, 85:942-949.